These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 16584516

  • 1. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
    Hovens GC, Buiting AM, Karperien M, Ballieux BE, van der Pluijm G, Pereira AM, Romijn JA, Smit JW.
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
    [Abstract] [Full Text] [Related]

  • 2. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M, Minich WB, Willenberg HS, Papewalis C, Seissler J, Feldkamp J, Bergmann A, Scherbaum WA, Morgenthaler NG.
    Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
    [Abstract] [Full Text] [Related]

  • 3. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
    Kamijo K, Murayama H, Uzu T, Togashi K, Olivo PD, Kahaly GJ.
    Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
    [Abstract] [Full Text] [Related]

  • 4. Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor.
    Morgenthaler NG, Pampel I, Aust G, Seissler J, Scherbaum WA.
    Horm Metab Res; 1998 Mar; 30(3):162-8. PubMed ID: 9566861
    [Abstract] [Full Text] [Related]

  • 5. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, Steuhl KP, Esser J, Morgenthaler NG.
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [Abstract] [Full Text] [Related]

  • 6. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N, Kamijo K, Sato Y, Yoshimura H, Nagata A, Ochi Y.
    Clin Exp Pharmacol Physiol; 2004 Nov; 31(5-6):314-9. PubMed ID: 15191404
    [Abstract] [Full Text] [Related]

  • 7. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE.
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [Abstract] [Full Text] [Related]

  • 8. Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies.
    Vitti P, Chiovato L, Fiore E, Mammoli C, Rocchi R, Pinchera A.
    Acta Med Austriaca; 1996 Dec; 23(1-2):52-6. PubMed ID: 8767515
    [Abstract] [Full Text] [Related]

  • 9. The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease.
    Lenzner C, Morgenthaler NG.
    Thyroid; 2003 Dec; 13(12):1153-61. PubMed ID: 14751037
    [Abstract] [Full Text] [Related]

  • 10. Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites.
    Morgenthaler NG, Ho SC, Minich WB.
    J Clin Endocrinol Metab; 2007 Mar; 92(3):1058-65. PubMed ID: 17179194
    [Abstract] [Full Text] [Related]

  • 11. Thyrotropin receptor antibodies detected by the human recombinant TBII assay--a surrogate marker for autoimmune activity in Graves' ophthalmopathy?
    Myśliwiec J, Kretowski A, Stepień A, Mirończuk K, Kinalska I.
    Med Sci Monit; 2002 Sep; 8(9):MT159-62. PubMed ID: 12218953
    [Abstract] [Full Text] [Related]

  • 12. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K, Yamazaki K, Yamada E, Kanaji Y, Miura M, Obara T.
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [Abstract] [Full Text] [Related]

  • 13. Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves' disease-a multicenter study.
    Diana T, Brown RS, Bossowski A, Segni M, Niedziela M, König J, Bossowska A, Ziora K, Hale A, Smith J, Pitz S, Kanitz M, Kahaly GJ.
    J Clin Endocrinol Metab; 2014 May; 99(5):1648-55. PubMed ID: 24517152
    [Abstract] [Full Text] [Related]

  • 14. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D, Massart C.
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [Abstract] [Full Text] [Related]

  • 15. Loss of variability in Graves' disease: stimulatory TSH-receptor antibodies bind to the TSH-receptor in a continued, non-pulsatile and non-chaotic fashion.
    Schuppert F, Diegelmann B, Geest T, Wagner TO, von zur Mühlen A.
    Chronobiologia; 1994 Jan; 21(1-2):21-32. PubMed ID: 7924634
    [Abstract] [Full Text] [Related]

  • 16. Epitope heterogeneity of thyrotropin receptor-blocking antibodies in Graves' patients as detected with wild-type versus chimeric thyrotropin receptors.
    Grasso YZ, Kim MR, Faiman C, Kohn LD, Tahara K, Gupta MK.
    Thyroid; 1999 Jun; 9(6):531-7. PubMed ID: 10411114
    [Abstract] [Full Text] [Related]

  • 17. Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease.
    Diana T, Krause J, Olivo PD, König J, Kanitz M, Decallonne B, Kahaly GJ.
    Clin Exp Immunol; 2017 Sep; 189(3):304-309. PubMed ID: 28439882
    [Abstract] [Full Text] [Related]

  • 18. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W, Man N, Li YS, Shan ZY, Teng WP.
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [Abstract] [Full Text] [Related]

  • 19. Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies.
    Diana T, Wüster C, Kanitz M, Kahaly GJ.
    J Endocrinol Invest; 2016 Oct; 39(10):1159-65. PubMed ID: 27197966
    [Abstract] [Full Text] [Related]

  • 20. Antibodies to TSH-receptor in thyroid autoimmune disease interact with monoclonal antibodies whose epitopes are broadly distributed on the receptor.
    Minich WB, Lenzner C, Morgenthaler NG.
    Clin Exp Immunol; 2004 Apr; 136(1):129-36. PubMed ID: 15030524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.